Corpus ID: 203558805

Duocarmycin Analogues into Potent Tumor Cytotoxins Specific Cytochrome P 450 2 W 1 Converts − Colon Cancer

  title={Duocarmycin Analogues into Potent Tumor Cytotoxins Specific Cytochrome P 450 2 W 1 Converts − Colon Cancer},
  author={Sandra Travica and Klaus Pors and Paul M. Loadman and Steven D. Shnyder and Inger Johansson and Mohammed N. Alandas and Helen M. Sheldrake and Souren Mkrtchian and Laurence H. Patterson and Magnus Ingelman-Sundberg},
Purpose: Cytochrome P450 2W1 (CYP2W1) is a monooxygenase detected in 30% of colon cancers, whereas its expression in nontransformed adult tissues is absent, rendering it a tumor-specific drug target for development of novel colon cancer chemotherapy. Previously, we have identified duocarmycin synthetic derivatives as CYP2W1 substrates. In this study, we investigated whether two of these compounds, ICT2705 and ICT2706, could be activated by CYP2W1 into potent antitumor agents. Experimental… 

Figures from this paper


Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
It is established that drug-activating CYP genes may be useful for the development of novel combined chemotherapy/gene therapy strategies for cancer treatment utilizing established cancer chemotherapeutic agents.
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.
CYP2W1 represents a tumor-specific P450 isoform with potential importance as a drug target in cancer therapy and was seen following demethylation by 5-Aza-2'-deoxycytidine.
Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy
The selective expression in some forms of cancers and the low expression in normal tissues render CYP2W1 as a possible drug target during cancer therapy.
CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
The results indicate that CYP-P450 isoforms play an important role in mediating benzothiazole activity, and CYP2W1 is important for bioactivation of GW-610 in CRC cells.
Cytochrome P450 1B1: a novel anticancer therapeutic target.
This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target and the therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a clinical trial.
Cytochrome P450s in the development of target-based anticancer drugs.
This review summarizes the merits and limitations of these expression systems for an optimized production of individual CYP isoforms, and their usefulness in the discovery and development of target-based, safe and efficacious NCEs for the treatment of cancer.
Expression of CYP2W1 in colon tumors: regulation by gene methylation.
The expression of CYP2W1 is colon tumor-specific and is associated with methylation status of the CYP1W1 gene, suggesting a potential causal link between the gene hypomethylation and its enhanced expression.
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
  • P. Roy, D. Waxman
  • Biology, Medicine
    Toxicology in vitro : an international journal published in association with BIBRA
  • 2006
P450 GDEPT has several important features that make it a clinically attractive strategy for cancer treatment, including the substantial bystander cytotoxicity of P450 prodrugs such as cyclophosphamide and ifosfamide, the ability to use human P450 genes and thereby avoid an immune response to the therapeutic gene, and the potential to decrease systemic exposure to active drug metabolites by selective inhibition of hepatic P450 activity.
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+
The introduction of p35 into gene therapeutic regimens constitutes an effective approach to increase bystander killing by cytochrome P450 gene therapy and may also be used to enhance other bystander cytotoxic therapies, including those involving the production of tumor cell toxic protein products.
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells
Results show that an enzyme playing a role in the L-serine biosynthesis could be implicated in colon cancer progression and chemoresistance and indicate that PSAT1 represents a new interesting target for CRC therapy.